Covered recipient · General Payments record
KEVIN L WINTHROP
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$415,021.28
110 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $397,768.80 | 82 |
| Travel and Lodging | $15,164.25 | 16 |
| Food and Beverage | $1,103.23 | 11 |
| Grant | $985.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $105,435.00 | 4 |
| ABBVIE INC. | $87,987.98 | 26 |
| UCB SA | $37,010.00 | 6 |
| Genentech, Inc. | $34,600.00 | 10 |
| ModernaTX, Inc. | $32,550.00 | 9 |
| Eli Lilly and Company | $27,233.08 | 11 |
| GlaxoSmithKline, LLC. | $21,659.95 | 10 |
| SANOFI US SERVICES INC. | $12,070.00 | 2 |
| Janssen Research & Development, LLC | $12,006.66 | 6 |
| BioMarin Pharmaceutical Inc. | $8,550.00 | 2 |
| F. Hoffmann-La Roche AG | $7,987.50 | 2 |
| Insmed, Inc. | $7,187.73 | 9 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $7,150.00 | 3 |
| Zambon USA Ltd. | $3,684.64 | 3 |
| AstraZeneca Pharmaceuticals LP | $3,575.00 | 1 |
| AstraZeneca UK Limited | $3,087.50 | 2 |
| Gilead Sciences, Inc. | $2,529.94 | 2 |
| Partner Therapeutics, Inc. | $710.00 | 1 |
| PFIZER INC. | $6.30 | 1 |
Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KEVIN L WINTHROP
NPI 1679509525 · CMS profile ID 257855
Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease
PORTLAND, OR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1679509525?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KEVIN L WINTHROP, NPI 1679509525, CMS profile ID 257855. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679509525?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). KEVIN L WINTHROP, NPI 1679509525, CMS profile ID 257855. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679509525?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- KEVIN L WINTHROP, NPI 1679509525, CMS profile ID 257855, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1679509525?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
110 matching records · $415,021.28 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 110.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| SANOFI US SERVICES INC. | $8,520.00 | 07/29/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139696276 | CMS |
| Janssen Research & Development, LLC | $1,950.00 | 07/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077590211 | CMS |
| ModernaTX, Inc. | $11,250.00 | 07/12/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152555493 | CMS |
| Janssen Research & Development, LLC | $1,662.50 | 07/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077588917 | CMS |
| Insmed, Inc. | $2,250.00 | 07/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089557002 | CMS |
| Insmed, Inc. | $163.98 | 07/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089564208 | CMS |
| PFIZER INC. | $6.30 | 06/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131272111 | CMS |
| GlaxoSmithKline, LLC. | $7,875.00 | 06/14/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115941603 | CMS |
| GlaxoSmithKline, LLC. | $358.53 | 06/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115998838 | CMS |
| GlaxoSmithKline, LLC. | $533.40 | 06/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116268946 | CMS |
| GlaxoSmithKline, LLC. | $193.02 | 06/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116708677 | CMS |
| GlaxoSmithKline, LLC. | $985.00 | 06/14/2024 | Grant | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116717455 | CMS |
| GlaxoSmithKline, LLC. | $1,420.00 | 06/05/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116207445 | CMS |
| Insmed, Inc. | $67.53 | 05/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089571204 | CMS |
| ABBVIE INC. | $3,600.00 | 05/20/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106349304 | CMS |
| BioMarin Pharmaceutical Inc. | $5,175.00 | 05/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127062952 | CMS |
| Genentech, Inc. | $3,275.00 | 05/14/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133048235 | CMS |
| Genentech, Inc. | $5,200.00 | 05/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133048252 | CMS |
| ABBVIE INC. | $6,035.00 | 04/29/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106349302 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22,720.00 | 04/25/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101345861 | CMS |
| Insmed, Inc. | $562.50 | 04/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089557004 | CMS |
| Genentech, Inc. | $2,840.00 | 04/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133048248 | CMS |
| Janssen Research & Development, LLC | $3,250.00 | 04/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077589279 | CMS |
| Eli Lilly and Company | $15,200.00 | 04/15/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135078189 | CMS |
| E.R. Squibb & Sons, L.L.C. | $29,465.00 | 04/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101345859 | CMS |
| ModernaTX, Inc. | $1,775.00 | 04/09/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152555473 | CMS |
| GlaxoSmithKline, LLC. | $1,420.00 | 04/03/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116380822 | CMS |
| E.R. Squibb & Sons, L.L.C. | $28,400.00 | 03/29/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101345853 | CMS |
| GlaxoSmithKline, LLC. | $5,200.00 | 03/22/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115888942 | CMS |
| GlaxoSmithKline, LLC. | $2,925.00 | 03/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116638750 | CMS |
| Genentech, Inc. | $5,200.00 | 03/18/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133048231 | CMS |
| Insmed, Inc. | $3,750.00 | 03/15/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089581630 | CMS |
| ABBVIE INC. | $710.00 | 03/07/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106349300 | CMS |
| F. Hoffmann-La Roche AG | $3,727.50 | 03/04/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133048223 | CMS |
| SANOFI US SERVICES INC. | $3,550.00 | 03/04/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139696278 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,575.00 | 02/27/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105621923 | CMS |
| Eli Lilly and Company | $133.38 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135078187 | CMS |
| Eli Lilly and Company | $277.80 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135104485 | CMS |
| Eli Lilly and Company | $329.00 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135104487 | CMS |
| Eli Lilly and Company | $69.91 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135104489 | CMS |
| Eli Lilly and Company | $133.38 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135104491 | CMS |
| Eli Lilly and Company | $329.00 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135111594 | CMS |
| Eli Lilly and Company | $277.80 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135133114 | CMS |
| Eli Lilly and Company | $69.91 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135134066 | CMS |
| Insmed, Inc. | $111.19 | 02/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089574980 | CMS |
| UCB SA | $1,420.00 | 02/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113950595 | CMS |
| Partner Therapeutics, Inc. | $710.00 | 02/21/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141329028 | CMS |
| AstraZeneca UK Limited | $2,600.00 | 02/14/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093925254 | CMS |
| Janssen Research & Development, LLC | $4,550.00 | 02/14/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077590213 | CMS |
| Genentech, Inc. | $3,900.00 | 02/13/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133048227 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $261,368.75 | 33 |
| PY2025 | Principal investigator | $403,130.29 | 72 |
| PY2024 | Recipient | $111,717.50 | 32 |
| PY2024 | Principal investigator | $1,484,791.73 | 279 |
| PY2023 | Recipient | $105,412.50 | 27 |
| PY2023 | Principal investigator | $394,404.53 | 166 |
| PY2022 | Recipient | $100,399.00 | 28 |
| PY2022 | Principal investigator | $3,202,007.70 | 149 |
| PY2021 | Recipient | $136,983.81 | 32 |
| PY2021 | Principal investigator | $1,496,429.40 | 79 |
| PY2020 | Recipient | $224,120.28 | 49 |
| PY2020 | Principal investigator | $46,760.48 | 13 |
| PY2019 | Recipient | $39,252.50 | 11 |
| PY2019 | Principal investigator | $118,643.36 | 26 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
105 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $4,615.00 | 12/31/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223263366 |
| Recipient | PFIZER INC. | $3,200.00 | 12/19/2025 | Covered Recipient Physician | TOFACITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727349 |
| Recipient | Genentech, Inc. | $5,200.00 | 12/16/2025 | Covered Recipient Physician | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | No dispute reported | 06/30/2026 | 1211537121 |
| Principal investigator 1 | bioMerieux Inc | $75,273.76 | 12/16/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489157 |
| Principal investigator 1 | bioMerieux Inc | $27,100.40 | 12/16/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489159 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $39,236.00 | 12/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | RD007067 | No dispute reported | 06/30/2026 | 1244347121 |
| Recipient | Genentech, Inc. | $3,575.00 | 12/05/2025 | Covered Recipient Physician | Gazyva for the treatment of MN | No dispute reported | 06/30/2026 | 1211537138 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $710.00 | 12/01/2025 | Covered Recipient Physician | PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) | No dispute reported | 06/30/2026 | 1225334751 |
| Recipient | ABBVIE INC. | $7,631.25 | 11/20/2025 | Covered Recipient Physician | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202402440 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $78,383.75 | 10/28/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | The immunogenicity and safety of Zostavax in rheumatoid arthritis patients using biologic therapy | No dispute reported | 06/30/2026 | 1236000414 |
| Recipient | Genentech, Inc. | $4,615.00 | 10/21/2025 | Covered Recipient Physician | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211537118 |
| Recipient | ABBVIE INC. | $4,537.50 | 10/09/2025 | Covered Recipient Physician | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202402436 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,130.00 | 10/08/2025 | Covered Recipient Physician | PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) | No dispute reported | 06/30/2026 | 1225334749 |
| Principal investigator 1 | Verona Pharma, Inc. | $16,753.94 | 10/03/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Verona | No dispute reported | 06/30/2026 | 1232892215 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $5,325.00 | 09/25/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223263364 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $54.60 | 09/24/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | RD007067 | No dispute reported | 06/30/2026 | 1186331195 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $27.22 | 09/18/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | RD007067 | No dispute reported | 06/30/2026 | 1186331305 |
| Principal investigator 1 | bioMerieux Inc | $31,350.00 | 09/16/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489153 |
| Principal investigator 1 | bioMerieux Inc | $29,929.00 | 09/16/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489155 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $4,400.00 | 09/15/2025 | Covered Recipient Physician | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223263362 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $8,640.20 | 09/07/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | RD007067 | No dispute reported | 06/30/2026 | 1186331281 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $496.13 | 09/04/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | RD007067 | No dispute reported | 06/30/2026 | 1186331241 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $3,905.00 | 08/29/2025 | Covered Recipient Physician | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223263360 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,970.00 | 08/13/2025 | Covered Recipient Physician | PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) | No dispute reported | 06/30/2026 | 1225334747 |
| Principal investigator 1 | bioMerieux Inc | $1,590.56 | 07/23/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489167 |
| Principal investigator 1 | bioMerieux Inc | $33.66 | 07/23/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489201 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,904.08 | 06/18/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Verona | No dispute reported | 06/30/2026 | 1232892076 |
| Recipient | NS Pharma, Inc. | $7,100.00 | 06/13/2025 | Covered Recipient Physician | Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | No dispute reported | 06/30/2026 | 1242700174 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $3,550.00 | 05/16/2025 | Covered Recipient Physician | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223263358 |
| Principal investigator 1 | Verona Pharma, Inc. | $8,604.72 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Verona | No dispute reported | 06/30/2026 | 1232892074 |
| Principal investigator 1 | bioMerieux Inc | $19.32 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489161 |
| Principal investigator 1 | bioMerieux Inc | $2.74 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489163 |
| Principal investigator 1 | bioMerieux Inc | $695.87 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489165 |
| Principal investigator 1 | bioMerieux Inc | $41.58 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489169 |
| Principal investigator 1 | bioMerieux Inc | $1,288.98 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489171 |
| Principal investigator 1 | bioMerieux Inc | $396.58 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489173 |
| Principal investigator 1 | bioMerieux Inc | $16.00 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489175 |
| Principal investigator 1 | bioMerieux Inc | $254.06 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489177 |
| Principal investigator 1 | bioMerieux Inc | $977.20 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489179 |
| Principal investigator 1 | bioMerieux Inc | $33.66 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489181 |
| Principal investigator 1 | bioMerieux Inc | $80.53 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489183 |
| Principal investigator 1 | bioMerieux Inc | $35.22 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489185 |
| Principal investigator 1 | bioMerieux Inc | $50.90 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489187 |
| Principal investigator 1 | bioMerieux Inc | $53.42 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489189 |
| Principal investigator 1 | bioMerieux Inc | $270.14 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489191 |
| Principal investigator 1 | bioMerieux Inc | $919.38 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489193 |
| Principal investigator 1 | bioMerieux Inc | $63.60 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489195 |
| Principal investigator 1 | bioMerieux Inc | $13.94 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489197 |
| Principal investigator 1 | bioMerieux Inc | $29.95 | 04/25/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Performance Evaluation of the VIDAS TB-IGRA Assay | No dispute reported | 06/30/2026 | 1253489199 |
| Recipient | Bausch Health US, LLC | $5,500.00 | 04/11/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224834969 |
| Recipient | Bausch Health US, LLC | $7,500.00 | 04/11/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224834973 |
| Recipient | Bausch Health US, LLC | $3,500.00 | 04/11/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224834977 |
| Recipient | Bausch Health US, LLC | $650.00 | 04/11/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224834981 |
| Recipient | Bausch Health US, LLC | $7,500.00 | 04/11/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224834986 |
| Principal investigator 1 | Verona Pharma, Inc. | $20,615.76 | 03/26/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | Verona | No dispute reported | 06/30/2026 | 1232892054 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $4,000.00 | 03/20/2025 | Covered Recipient Physician | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184123952 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $100,465.00 | 03/18/2025 | Covered Recipient Physician | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs | No dispute reported | 06/30/2026 | 1242720071 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $3,550.00 | 03/03/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223263356 |
| Principal investigator 1 | Insmed, Inc. | $205.70 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646366 |
| Principal investigator 1 | Insmed, Inc. | $850.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646470 |
| Principal investigator 1 | Insmed, Inc. | $300.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646472 |
| Principal investigator 1 | Insmed, Inc. | $300.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646474 |
| Principal investigator 1 | Insmed, Inc. | $850.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646476 |
| Principal investigator 1 | Insmed, Inc. | $2,200.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646478 |
| Principal investigator 1 | Insmed, Inc. | $650.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646480 |
| Principal investigator 1 | Insmed, Inc. | $1,280.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646482 |
| Principal investigator 1 | Insmed, Inc. | $320.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646484 |
| Principal investigator 1 | Insmed, Inc. | $300.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646486 |
| Principal investigator 1 | Insmed, Inc. | $677.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646488 |
| Principal investigator 1 | Insmed, Inc. | $850.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646490 |
| Principal investigator 1 | Insmed, Inc. | $2,200.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646492 |
| Principal investigator 1 | Insmed, Inc. | $850.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646494 |
| Principal investigator 1 | Insmed, Inc. | $850.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646496 |
| Principal investigator 1 | Insmed, Inc. | $850.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646498 |
| Principal investigator 1 | Insmed, Inc. | $850.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646500 |
| Principal investigator 1 | Insmed, Inc. | $850.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646502 |
| Principal investigator 1 | Insmed, Inc. | $2,200.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646504 |
| Principal investigator 1 | Insmed, Inc. | $300.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646506 |
| Principal investigator 1 | Insmed, Inc. | $25.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646508 |
| Principal investigator 1 | Insmed, Inc. | $650.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646510 |
| Principal investigator 1 | Insmed, Inc. | $25.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646512 |
| Principal investigator 1 | Insmed, Inc. | $550.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646514 |
| Principal investigator 1 | Insmed, Inc. | $850.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646516 |
| Principal investigator 1 | Insmed, Inc. | $200.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646518 |
| Principal investigator 1 | Insmed, Inc. | $500.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646520 |
| Principal investigator 1 | Insmed, Inc. | $300.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646522 |
| Principal investigator 1 | Insmed, Inc. | $800.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646524 |
| Principal investigator 1 | Insmed, Inc. | $25.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646526 |
| Principal investigator 1 | Insmed, Inc. | $25.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646528 |
| Principal investigator 1 | Insmed, Inc. | $600.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646530 |
| Principal investigator 1 | Insmed, Inc. | $25.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646532 |
| Principal investigator 1 | Insmed, Inc. | $450.00 | 02/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646534 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $25,560.00 | 02/18/2025 | Covered Recipient Physician | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1236001919 |
| Principal investigator 1 | Paratek Pharmaceuticals, Inc. | $5,620.00 | 02/13/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex | No dispute reported | 06/30/2026 | 1181710972 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,380.00 | 02/05/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185543174 |
| Recipient | Bausch Health US, LLC | $4,500.00 | 01/24/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224834948 |
| Recipient | Bausch Health US, LLC | $8,000.00 | 01/24/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224834953 |
| Recipient | Bausch Health US, LLC | $3,500.00 | 01/24/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224834957 |
| Recipient | Bausch Health US, LLC | $2,500.00 | 01/24/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224834961 |
| Recipient | Bausch Health US, LLC | $7,000.00 | 01/24/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224834965 |
| Recipient | Genentech, Inc. | $2,600.00 | 01/23/2025 | Covered Recipient Physician | Gazyva for the treatment of MN | No dispute reported | 06/30/2026 | 1211537130 |
| Recipient | Genentech, Inc. | $2,840.00 | 01/21/2025 | Covered Recipient Physician | Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE | No dispute reported | 06/30/2026 | 1211537126 |
| Recipient | Genentech, Inc. | $3,900.00 | 01/21/2025 | Covered Recipient Physician | Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE | No dispute reported | 06/30/2026 | 1211537134 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,840.00 | 01/16/2025 | Covered Recipient Physician | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223263354 |
| Principal investigator 1 | Paratek Pharmaceuticals, Inc. | $22,135.74 | 01/09/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex | No dispute reported | 06/30/2026 | 1181710970 |